Experience with rituximab in the treatment of systemic erythematosus lupus;Experiencia con rituximab en el tratamiento de pacientes con lupus eritematoso sistémico

Reumatologia Clinica

Volumn 2, Issue 1, 2006, Pages 23-30

  Garcia Hernandez F J ^a   Diaz Cobos C ^b   Callejas Rubio, J L ^c   Ocana Medina C ^a   Ortego Centeno, N ^c   Sanchez Roman J ^a   de Ramon Garrido E ^b   Camps Garia M T ^b  

^a HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^b HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

^c HOSPITAL UNIVERSITARIO SAN CECILIO   (Spain)

Author keywords

Anti CD20; Nephritis; Rituximab; Systemic lupus erythematosus; Thrombocytopenia

Indexed keywords

RITUXIMAB;

ADULT; APLASTIC ANEMIA; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; COLITIS; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE SEVERITY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG INDICATION; DRUG TOLERANCE; FEMALE; FOLLOW UP; HUMAN; INFECTION; MALE; NEPHRITIS; NEPHROTIC SYNDROME; RECURRENT DISEASE; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOCYTOPENIA; VASCULITIS;

EID: 33644946072     PISSN: 1699258X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1699-258X(06)73016-9     Document Type: Article

References (28)

1. Cervera R, Khamashta MA, Font J, Sebastiani GD, Gil A, Lavilla P, et al and; European Working Party on Systemic Lupus Erythematosus. Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients. Medicine (Baltimore). 2003;82:299-308.
2. Chan O, Sclomchik MJ. A new role for B cells in systemic autoimmunity: B cell promote spontaneous T cell activation in MRL-lpr/lpr mice. J Immunol. 1998;160:51-9.
3. Odendahl M, Jacobi A, Hansen A, Feist E, Hiepe F, Burmester GR, et al. Disturbed peripheral B lymphocyte homeostasis in systemic lupus erythematosus. J Immunol. 2000;165:5970-9.
4. Reff ME, Carner K, Chambers KS, Chinn PC, Leonard JE, Raab R, et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood. 1994;83:435-45.
5. Edwards JC, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close DR, et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med. 2004;350:2572-81.
6. Germing U, Sohngen D, Qualreck K, Aul C. Treatment of relapsed idiopathic thrombocytopenic purpura with the anti-CD20 monoclonal anti-body rituximab: a pilot study. Giagounidis AA, Anhuf J, Schneider Eur J Haematol. 2002;69:95-100.
7. Berentsen S, Ulvestad E, Gjertsen BT, Hjorth-Hansen H, Langholm R, Knutsen H, et al. Rituximab for primary chronic cold agglutinin disease: a prospective study of 37 courses of therapy in 27 patients. Blood. 2004;103:2925-8.
8. Keogh KA, Wylam ME, Stone JH, Specks U. Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum. 2005;52:262-8.
9. Lamprecht P, Lerin-Lozano C, Merz H, Dennin RH, Gause A, Voswinkel J, et al. Rituximab induces remission in refractory HCV associated cryoglobulinaemic vasculitis. Ann Rheum Dis. 2003;62:1230-3.
10. Pestronk A, Florence J, Miller T, Choksi R, Al-Lozi MT, Levine TD. Treatment of IgM antibody associated polyneuropathies using rituximab. J Neurol Neurosurg Psychiatry. 2003;74:485-9.
11. Ruggenenti P, Chiurchiu C, Brusegan V, Abbate M, Perna A, Filippi C, et al. Rituximab in idiopathic membranous nephropathy: a one-year prospective study. J Am Soc Nephrol. 2003;14:1851-7.
12. Barquero-Romero J, Garcia Dominguez M, Perez Miranda M. Efficacy of therapy with anti-CD20 antibody (rituximab) in a patient with autoimmune hemolytic anemia associated. Med Clin. 2005;124:517-8.
13. Levine TD. Rituximab in the treatment of dermatomyositis: an open-label pilot study. Arthritis Rheum. 2005;52:601-7.
14. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythe-matosus. Arthritis Rheum. 1982;25:1271-7.
15. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum. 1992;35:630-40.
16. Gottenberg J, Guillevin L, Lambotte O, Combe B, Allanore Y, Cantagrel A, et al. Tolerance and short-term efficacy of rituximab in 43 patients with systemic autoimmune diseases. Ann Rheum Dis Published Online 2004. 10.1136/ard.2004.029694.
17. Looney RJ, Anolik JH, Campbell D, Felgar RE, Young F, Arend LJ, et al. 13 cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab. Arthritis Rheum. 2004;50:2580-9.
18. Looney RJ. Treating human autoimmune disease by depleting B cells. Ann Rheum Dis. 2002;61:863-6.
19. Leandro MJ, Edwards JC, Cambridge G, Ehrenstein MR, Isenberg DA. An open study of B lymphocyte depletion in systemic lupus erythematosus. Arthritis Rheum. 2002;46:2673-7.
20. Anolik JH, Campbell D, Ritchlin C, Holyst M, Rosenfeld S, Varnis C, et al. B lymphocyte depletion as a novel treatment for systemic lupus erythematosus (SLE): phase I/II trial of rituximab (Rituxan®) in SLE. Arthritis and Rheumatism. 2001;44 9 Supl:387S.
21. SfikAkis PP, Boletis JN, Lionaki S, Vigklis V, Fragiadaki KG, Iniotaki A, et al. Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: an open-label trial. Arthritis Rheum. 2005;52:501-13.
22. Cheng Y, Wong RS, Soo YO, Choi CH, Lau FY, Chan NP, et al. Initial treatment of immune thrombocytopenic purpura with high-dose dexamethasone. N Engl J Med. 2003;349:831-6.
23. Cooper N, Stasi R, Cunningham-Rundles S, Feuerstein MA, Leonard JP, Amadori S, et al. The efficacy and safety of B-cell depletion with anti-CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura. Br J Haematol. 2004;125-232-9.
24. Rose AL, Smith BE, Maloney DG. Glucocorticoids and rituximab in vitro: synergistic direct antiproliferative and apoptotic effects. Blood. 2002;100:1765-73.
25. Perrotta S, Locatelli F, La Manna A, Cennamo L, De Stefano P, Nobili B. Anti-D20 monoconal antibody (Rituximab) for life-threatining autoimmune haemolytic, anemia in a patient with systemic lupus erytematosus. Br J Hematol. 2002;116:465-7.
26. Saigal K, Valenica IC, Cohen J, Kerdel F. Hypocomplementemic urticarial vasculitis with angioedema, a rare presentation of systemic lupus erythematosus: rapid response to rituximab. J Am Acad Dermatol. 2003;49:S283-5.
27. Saito K, Nawata M, Nakayamada S, Tokunaga M, Tsukada J, Tanaka Y. Lupus. Successful treatment with anti-CD20 monoclonal antibody (rituximab) of life-threatening refractory systemic lupus erythematosus with renal and central nervous system involvement. 2003;12:798-800.
28. Weide R, Heymanns J, Pandorf A, Koppler H. Successful long-term treatment of systemic lupus erythematosus with rituximab maintenance therapy. Lupus. 2003;12:779-82.